Idenix Pharmaceuticals (IDIX)

[hansfinans]

<Expect NVS to buyout IDIX $9 - $13 / share>

normally when we have a buy out in this sector we see a premium of 40 to 60 percent to shareholders, e.g. Mederex and IDM pharma recently..

Why believe that Novartis wants to go far beyont this and play Santa Claus here in mid summer offering a premium of 400 percent. It seems to me, unfortunately, mostly as wishful thinking. And it seems also a bit to optimsitic for the marked in general - Close today at 2.79 POS